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ORIGINAL ARTICLE
Measurement of bronchial hyperreactivity: comparison of three Nordic
dosimetric methods
Paul G. Lassmann-Kleea , Britt-Marie Sundbladb , Leo P. Malmbergc , Anssi R. A. Sovij€arvia and
P€aivi Piiril€aa
aUnit of Clinical Physiology, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland; bThe National Institute of
Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; cLaboratory of Clinical Physiology, Skin and Allergy Hospital,
Helsinki, Finland
ABSTRACT
Clinical testing of bronchial hyperreactivity (BHR) provides valuable information in asthma diagnostics.
Nevertheless, the test results depend to a great extent on the testing procedure: test substance,
apparatus and protocol. In Nordic countries, three protocols predominate in the testing field: Per
Malmberg, Nieminen and Sovij€arvi methods. However, knowledge of their equivalence is limited. We
aimed to find equivalent provocative doses (PD) to obtain similar bronchoconstrictive responses for
the three protocols. We recruited 31 patients with suspected asthma and health care workers and per-
formed BHR testing with methacholine according to Malmberg and Nieminen methods, and with his-
tamine according to Sovij€arvi. We obtained the individual response-dose slopes for each method and
predicted equivalent PD values. Applying a mixed-model, we found significant differences in the mean
(standard error of mean) response-dose (forced expiratory volume in one second (FEV1)%/mg):
Sovij€arvi 7.2 (1.5), Nieminen 13.8 (4.2) and Malmberg 26 (7.3). We found that the earlier reported cut-
point values for moderate BHR and marked BHR between the Sovij€arvi (PD15) and Nieminen (PD20)
methods were similar, but with the Malmberg method a significant bronchoconstrictive reaction was
measured with lower PD20 values. We obtained a relationship between slope values and PD (mg)
between different methods, useful in epidemiological research and clinical practice.
Abbreviations: ANOVA: analysis of variance; BHR: bronchial hyperreactivity; CI: confidence interval;
FENO: fractional exhaled nitric oxide; FEV1: forced expiratory volume in one second; IQR: interquartile
range; MMAD: mass median aerodynamic diameter; NTP: normal temperature and pressure; PD: pro-
vocative dose; SEM: standard error of the mean
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Introduction
Bronchial challenge testing with inhaled methacholine (chlor-
ide or bromide) and histamine diphosphate may provoke
bronchoconstriction. This transient alteration of pulmonary
function is expressed as a reduction of the forced expiratory
volume in one second (FEV1). An absent bronchoconstrictive
reaction to these substances usually indicates an absence of
current asthma in test subjects [1]. Inversely, a positive bron-
chial reaction concomitant with current symptoms can con-
firm an asthma diagnosis. Decades of bronchial
hyperreactivity (BHR) testing with histamine or methacho-
line, acting directly on the bronchial histamine or cholinergic
wall receptors, came hand in hand with different testing pro-
tocols and equipment. In two Nordic countries, three dosi-
metric protocols employed in clinical settings possess
noteworthy methodological differences: methacholine testing
with a nebuliser and a drying device developed by Per
Malmberg et al. [2], methacholine testing with a jet dosimeter
according to Nieminen et al. [3] and histamine testing with
the same dosimeter according to Sovij€arvi et al. [4]. Previous
researchers have compared the Sovij€arvi and Nieminen meth-
ods in an epidemiological setting [5], but the lack of further
quantitative comparisons has resulted in limited knowledge
of their equivalence, as well as a missing comparison with the
Malmberg method. Through early studies, similarities
between histamine and methacholine as provocative agents
are well known [6]. Nevertheless, comparison of the afore-
mentioned protocols is a challenging task, considering that
the endpoint level (provocative dose) varies between proto-
cols and there are inherent differences in the testing substan-
ces, such as molecular mass and pharmacodynamics. A direct
translation between provocative doses may yield erroneous
interpretations. Therefore, a comparison study was needed.
The aim of this study was to find equivalent dose-
response slopes and provocative dose values between the
methods, for the same levels of bronchial response.
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Methods
We recruited prospectively 31 volunteers, either patients
with a referral for BHR testing or healthcare workers and
included fractional exhaled nitric oxide (FENO) values from
medical records if available.
We assessed BHR on the volunteers, employing two pro-
tocols with methacholine (Malmberg and Nieminen) and
one protocol with histamine (Sovij€arvi), all methods com-
monly employed in Finland, Sweden and Estonia. The chal-
lenge tests were performed in the Helsinki University
Central Hospital area, Finland including the Skin and
Allergy Hospital and the Laboratory of Clinical Physiology
at the Meilahti Hospital, Finland. For each participant, the
three challenge tests were scheduled within a two weeks
period, with a minimum time interval of three days. The
order of the challenge tests was based on the availability of
the appointment times, with a fixed testing hour during the
morning. Prior to BHR testing, the participants discontin-
ued sympathomimetic and antimuscarinic medication
according to the ATS technical standard [7], and withheld
antihistamines for at least five days. We followed the recent
safety and quality standards [8]. Additionally, the partici-
pants refrained from ingesting coffee, tea and cola for 4 h,
alcohol for 24 h, and heavy meals or smoking 2 h before the
challenge, in agreement with our laboratory guidelines.
Furthermore, BHR was tested at least one month after any
respiratory infections. The testing phase was during fall and
winter seasons.
All participants signed a written consent agreement and
the Helsinki University Hospital Ethical Committee
approved our project (HUS 1417/2016). We followed the
ethical principles stated in the Declaration of Helsinki [9].
We determined a minimum of 30 participants in our
study to achieve a statistical power of 80% for detecting an
effect size of 0.25 (Cohen’s d) and an a error of 5% if con-
sidering repeated measurements with three methods and
testing the difference between methods with an analysis of
variance (ANOVA) test (GPower 3.1.9.4 software)[10].
Bronchial hyperreactivity protocols
Per Malmberg methacholine test
The device (Figure 1) developed by Malmberg et al. [2],
employs a drying device, a polymethyl methacrylate tower
(Nova Plast, Karlskoga, Sweden) with 3.4 l volume and a
Sidestream Durable jet nebuliser (Medic Aid Ltd, West
Sussex, UK). The nebuliser chamber’s aerosol is driven by
pressurised medical air (AGA, Espoo, Finland), supplied
from a gas cylinder adjusted at 1.6 bar pressure, providing a
primary flow towards the nebuliser of 8.7 l/min (20 C,
NTP). The Venturi-flow of 15.3 l/min (20 C, NTP) is
adjusted by a Fischer and Porter rotameter (ABB Limited,
Cambridgeshire, UK). These settings give a total flow in the
drying device of 24 l/min and deliver the aerosol to the
mouthpiece at the top of the tower. The mass output was
determined gravimetrically, filling 3ml of Aqua and nebuli-
sation during 1min, and set to 0.5–0.6ml/min (20 C,
NTP). Reported mass median aerodynamic diameter
(MMAD) for this setting is 1.7 mm [2,11]. Further on, the
mass output was corrected with the efficiency coefficient
0.75, previously defined by Eklund et al. [11].
Before the methacholine challenge (5min), FEV1 was
determined by spirometry (Masterscreen, Jaeger GmbH,
W€urzburg, Germany). The dose delivered during 1min was
controlled through 15 tidal inspirations and expirations,
each lasting 2 s and synchronised by a metronome, equiva-
lent to 0.5min total inhalation time and 0.8 l volume per
inhalation [12]. The delivered dose was determined by the
product of the mass output (ml/min), the delivery time
(0.5min) and the methacholine concentration of the solu-
tion (mg/ml). The challenge started with 3ml isotonic
sodium chloride solution and the methacholine concentra-
tion was increased in doubling steps: 0.5, 1, 2, 4, 8, 16 and
32mg/ml, respectively. The non-cumulated doses inhaled
(after correction with the efficiency coefficient) at each step
were: 0.1125, 0.225, 0.45, 0.9, 1.8, 3.6 and 7.2mg, respect-
ively. Accordingly, the cumulated doses were: 0.1125,
0.3375, 0.7875 , 1.6875 , 3.4875, 7.0875 and 14.2875mg,
respectively.
Figure 1. Installation of the methacholine testing equipment according to
Malmberg (#Pia Saarenkoski).
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FEV1 was acquired 4min after starting the inhalation of
each dose. The time between doubling concentrations was
6min. The challenge was performed until achieving a min-
imum reduction of 20% in FEV1 or until reaching the high-
est concentration of 32mg/ml. The methacholine chloride
solution employed (2-acetyloxypropyl(trimethyl)azanium;
chloride) was prepared by the Helsinki University
Hospital’s pharmacy.
Nieminen methacholine test
The protocol developed by Nieminen et al. [3] employs a
dosimetric Spira Elektro 2 automatic jet nebuliser device
(Respiratory Care Centre, H€ameenlinna, Finland; Figure 2),
driven by pressurised medical air at 2 bar and providing a
primary flow towards the nebuliser of 7.5 l/min (20 C,
NTP). It produces a MMAD of 1.6 mm [13]. According to
this protocol, the inhalation-synchronised-dosimeter delivers
methacholine over 0.5 s triggered by tidal breath, controlled
during nebulisation with an optimal inspiratory peak flow-
rate of 0.5 l/s and employs an inspiratory volume of at least
0.4 l. The optimal inspiratory flow level is visually con-
trolled. In a five-step concentration increment, this setting
provides cumulative doses of: 0.018, 0.072, 0.27, 0.81 and
2.6mg, respectively. The five steps are: one inhalation at
2.5mg/ml, three inhalations at 2.5mg/ml, 11 inhalations at
2.5mg/ml, three inhalations at 25mg/ml and 10 inhalations
at 25mg/ml. The non-cumulated doses inhaled in the five
steps are: 0.018, 0.054, 0.198, 0.540 and 1.78mg, respectively
[14]. The time between the steps is 5min. The mass output
was determined gravimetrically [14].
Before the methacholine challenge (5min), FEV1 was
determined by spirometry (Masterscreen). After each step of
the challenge, an FEV1 value was obtained. The challenge
test was performed until achieving a minimum reduction of
20% in FEV1 or until reaching the highest dose of 2.6mg.
Sovij€arvi histamine test
Sovij€arvi et al. [4] established a rapid tidal-breathing-con-
trolled dosimetric protocol with buffered histamine diphos-
phate as the provocative agent. The Sovij€arvi method also
utilises the aforementioned Spira Elektro 2 dosimeter with
the following settings: drug delivery time 0.4 sec, starting
inhalation volume 100ml, controlled inspiratory volume of
at least 0.5 l and inspiratory peak flow 0.5 l/s. The optimal
inspiratory flow level is visually controlled. These settings
produce, in fourfold increasing concentration increments,
non-cumulative doses of 0.025, 0.1, 0.4 and 1.6mg, respect-
ively. The four steps are: one inhalation at 4mg/ml, one
inhalation at 16mg/ml, four inhalations at 16mg/ml and 16
inhalations at 16mg/ml. The interval between steps is 5min.
The mass output was determined by weight [4].
Prior to histamine challenge testing (5min), FEV1 was
obtained by spirometry (Masterscreen). FEV1 was measured
after each dose, and the test continued until the onset of a
15% reduction in FEV1 or until the highest dose of 1.6mg
was given.
The Helsinki University Hospital’s pharmacy delivered
the buffered histamine phosphate solution (2-(1H-imidazol-
5-yl)ethanamine; phosphoric acid).
Provocative dose
The provocative doses (PD) for each positive test were cal-
culated (i.e. 15% FEV1 reduction for histamine (PD15) and
20% FEV1 reduction for methacholine (PD20)). We per-
formed a two-point logarithmic interpolation of PD20 with
the Equation (1):
PD20 ¼ e
ln D1ð Þþ ln D2ð Þln D1ð Þð Þ 20R1ð ÞR2R1ð Þ
h i
(1)
with D1 being the second to last dose (one step before D2),
D2 the last dose provoking at least a 20% reduction in
FEV1, R1 the FEV1 change in % measured after D1 and R2
the FEV1 change in % measured after D2 [8].
For the histamine challenge test, the provocative dose
causing a 15% reduction in FEV1 (PD15) was calculated
with Equation (1), by substituting 20 with 15.
The provocative dose was not calculated for subjects not
achieving a significant reduction in FEV1 (i.e. 20% with
methacholine and 15% with histamine). Nevertheless, we
obtained response-dose slopes for all subjects (see statis-
tics below).
The doses for the methacholine BHR tests are cumulative,
since methacholine is regarded as partially having a cumula-
tive effect [15–17] during the testing time of 5–6min.
Additionally, the original protocols describe cumulative doses
Figure 2. Spira Elektro 2 dosimeter employed in the Sovij€arvi and Nieminen
testing protocols.
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for methacholine. Histamine is rapidly metabolised [15,17],
showing no significant cumulative effect and the doses deliv-
ered are regarded in the model as non-cumulative.
Nevertheless, since the ERS technical standard on bronchial
challenge testing recommends a non-cumulative approach on
PD [8], non-cumulative PDwere also calculated.
Statistics
Using the R language [18] and Rstudio frontend version
1.1.383 (Boston, MA), we analysed the three protocols
applying a mixed-effect model with crossed and nested
effects (mathematical notation of the model is specified in
the Supplementary Appendix A). The doses given for each
subject are nested within each protocol and our study
design specifies a crossed model, (i.e. every subject is tested
with each protocol). The model defines random slopes for
individual subjects, expressing the changes in FEV1 in per-
cent per dose of the substance in milligrams. The intercepts
were suppressed from the model, since physiologically the
changes in FEV1 for each subject started from zero (a base-
line FEV1 value of 100%). The mixed model was analysed
with the lmer function from the lme4 package [19], and we
obtained the restricted maximum likelihood (REML) esti-
mates. The p values for the fixed effects were calculated
with the Satterthwaite’s method from the lmerTest pack-
age [20].
We extracted the slopes (FEV1%/mg) for each subject
and protocol and compared the differences in the log-trans-
formed slopes between protocols with an ANOVA, passing
the assumptions with a Shapiro-Wilk test, a Bartlett test and
a Fligner-Killeen test. The untransformed slopes were tested
for differences with a Kruskal-Wallis Rank Sum test.
Furthermore, we fitted the slopes to a non-linear model
with the obtained PD15 or PD20 as dependent variables. We
specified a non-linear model for each protocol and applied
the non-linear models to predict equivalent PD values
between protocols, based on the slopes. We analysed the
non-linear models with the Levenberg-Marquardt nonlinear
least-squares algorithm nlsLM from the minipack.lm pack-
age [21]. We regarded a¼ 0.05 as a significant level.
Results
The 28 participants completed the three challenges, except
three participants, who omitted one methacholine test
(Nieminen). No severe adverse reactions were observed. The
characteristics of this population, including spirometric val-
ues are summarised in Table 1. The standard error of the
mean (SEM) response in 31 subjects to histamine was a
7.2% (1.5) reduction in FEV1 per milligram. A 1mg dose of
methacholine caused a mean 13.8% (4.2) reduction in FEV1
with the Nieminen method in 28 subjects and a 26% (7.3)
reduction in FEV1 with the Malmberg method in 31 sub-
jects. These fixed effects are visualised in Figure 3. The
mixed model (see Supplementary Appendix A) had an R2 of
0.99, i.e. explaining 99% of the variance in our population.
The observed power of the model for the fixed effects
was 97%.
The slopes (FEV1%/mg) were extracted from the model
for each subject and separately for each method, and the
individual slopes from the model and the individual
response-dose measurements were plotted and arranged
according to their steepness and can be found in the
Supplementary Appendix A (Figures A1–A3). We found in
Table 1. Study participants’ demographics, spirometric, anthropometric data, medication and fractional expiratory nitric oxide
(FENO) values.
n Median (IQR) Spirometry n Median (IQR) Range
Age (years) 31 42 (29) FVC (l) 31 4.1 (2.3) 2.6–7.0
Height (cm) 31 171 (14) FVC (%)a 31 95 (18) 73–125
Weight (kg) 31 72 (20) FEV1 (l) 31 2.9 (1.4) 1.9–5.6
Female/Male 18/13 58%/42% FEV1 (%)
a 31 90 (21) 71–117
Asthma 4 13% FEV1/FVC ratio 31 0.78 (0.5) 0.66–0.91
Allergic rhinitis 12 39% FEV1/FVC (%
a) 31 94 (7) 84–106
Smoking 4 13% FENO (ppb)
b 25 19 (11) 5–63
Salbutamol 5 16%
Antihistamines 4 13%
Budesonide 1 3%
Data presented as median (interquartile range) or percentage of total case number.
aPercentage of predicted value [45].
bMeasured at expiratory flow rate 50ml/s.
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Figure 3. Dose (mg) provoking FEV1 changes from baseline (%) for each sub-
stance. Lines depict the fixed effects from the mixed model and shaded area
the 95% confidence interval.
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testing with the non-parametric test between methods that,
the differences in slopes (within-subjects) were not statistic-
ally significant (p¼ .22). The ANOVA of the log-trans-
formed slopes produced similar results (p¼ .3). The
distribution of all measured FEV1 responses for the three
methods is plotted in Figure 4.
Fitting non-linear models to the PD and the extracted
slopes resulted in the following regression equations:
Methacholine Malmberg PD20 ¼ e3:0897  slope1:05721 (2)
Methacholine Nieminen PD20 ¼ e3:6279  slope1:3257 (3)
Histamine Sovijärvi PD15 ¼ e3:4906  slope1:3773 (4)
where slope is the individual slope denoting the changes in
FEV1 in percent per dose (mg) of inhaled substance, for the
specific protocol and method. The estimates for the three
models were statistically significant on the p< .001 level.
Figure 5 exemplifies the model for methacholine and the
Malmberg method (Equation (2)). The PD values employed
for obtaining the models were the calculated PD values for
the participants. These PD values were positive (i.e. 15%
FEV1 reduction for histamine (PD15) and 20% FEV1 reduc-
tion for methacholine (PD20) with the highest dose) in 77%
of the subjects with the Malmberg method, in 36% with the
Nieminen method and 26% with the Sovij€arvi method.
Table 2 shows the percentages of PD values with or without
significant FEV1 decrease.
We predicted a series of PD15 and PD20 values with equal
slopes utilising the Equations (2)–(4). These equivalent pre-
dicted provocative dose values are presented in Table 3
(selected cut-point values) and extensively in Table A1 in
Supplementary Appendix A.
Non-cumulative results for PD and tables can be found
in Supplementary Appendix B.
Discussion
Mean reduction in FEV1 in the three dosimetric methods
We found that the response-dose relationship in the assess-
ment of BHR was different between the methods when ana-
lysing the fixed effects (i.e. the mean FEV1 changes per
milligram of test substance independent from the individual
responses). The Malmberg method produced the greatest
reduction in FEV1 per milligram, followed by the Nieminen
method, both employing methacholine as the test substance.
The Sovij€arvi method with histamine produced the least
changes per milligram. Preceding studies argue that when
considering the molar masses of histamine and methacho-
line, their effect is roughly equivalent when employing the
same protocol and device [6]. Our results also indicate simi-
larities when applying molar masses instead of mass (mg) to
the Sovij€arvi and Nieminen protocols, which utilise an iden-
tical device and considering a small disagreement probably
originating from the characteristics of the substances used,
since, as earlier reported, methacholine may partially have a
cumulative effect and histamine not. Analysing the distribu-
tion of the FEV1 responses reveals similar curves for the
Sovij€arvi and Nieminen methods, but the Malmberg protocol
produced a higher frequency of FEV1 responses over 20
0.00
0.05
0.10
0.15
0 10 20 30 40 50
FEV1 changes in % from baseline
D
en
si
ty
Method
Sovijärvi
Malmberg
Nieminen
Figure 4. Distribution (density) of all measured FEV1 changes in percent for the
Sovij€arvi, Malmberg and Nieminen methods.
Table 2. Provocative doses (PD) classified according to the studied methods
in our study population (n¼ 31).
Method No reaction Mild Moderate Marked reaction
Methacholine Malmberg 7 (23%) 14 (45%) 10 (32%)
Methacholine Nieminen 18 (64%) 6 (21%) 3 (11%) 1 (4%)
Histamine Sovij€arvi 23 (74%) 7(23%) 1 (3%) 0
PD20 = e
3.0897 ×  Slope−1.05721
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Figure 5. Non-linear regression modelling (Equation (1)) of individual
response-dose slopes, (i.e. FEV1 changes in percent per mg of methacholine
and PD20 in mg with the Malmberg Method), N¼ 31.
Table 3. Predicted equivalent provocative doses (mg) and corresponding
slope values.
Response categories
Slope (FEV1 % /mg)
PD20 (mg) PD20 (mg) PD15 (mg)
Methacholine
Malmberg
Methacholine
Nieminen
Histamine
Sovij€arvi
7.5 2.6 2.6 2.1
9.0 2.2 2.0 1.6
23.5 0.8 0.6 0.4
30.5 0.6 0.4 0.3
65.0 0.3 0.15 0.1
Bold provocative doses (PD) are reference cut-off values from the original
publications (see the following grading). Malmberg: asthmatic, PD20< 0.6mg;
normal, >0.6mg. Nieminen: no reaction, PD20> 2.6mg; mild, 2.6–0.61mg;
moderate, 0.60–0.151mg; marked, 0.15mg. Sovij€arvi: no reaction,
PD15> 1.6mg; mild, 1.6–0.41mg; moderate, 0.40–0.11mg; marked, 0.1mg.
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percent from the baseline. Malmberg et al. [2] developed the
drying tower to improve the efficacy of the device and
reported a 1.6-fold greater response in FEV1 changes than
without the drying tower. This partly supports our findings
concerning the differences between the methacholine proto-
cols. It may be speculated that the afore-mentioned overall
differences for the Malmberg methodology may result from
an indirect stimulus caused by dry-air. This indirectly acting
bronchoconstrictive effect of mucosal dehydration [22] may
sum up with the direct effect of methacholine on airway
smooth muscle.
We employed mass (mg) and the accumulation as in the
original protocols, despite their differences, because our
main aim was to find corresponding PD in milligram, as
near as the clinically employed protocols. For informational
purposes, additional guideline-accurate non-cumulative PD’s
was provided, with corresponding response-dose slopes.
These non-cumulative values are very near to the cumulative
values, supporting the fact, that the cumulative effect of
methacholine is very limited within the testing times [8].
Furthermore, the assumption of delivered doses in all the
investigated methods were originally based on gravimetric
measurements, which are inaccurate, since gravimetrical esti-
mation of the mass output ignores evaporation, resulting in
over-estimation of the mass output and the dose also. From
this fact originates some degree of discrepancies between
methods that is expressed as differences in PD values. The
Malmberg protocol includes an adjustment considering
evaporation [11]. Evaporation values for the Sovij€arvi and
Nieminen methods are not currently available. Nevertheless,
all the three methods have reported MMAD values, which
are almost identical and therefore the issue of different
particle sizes affecting the bronchial response could
be eliminated.
Response categories
Reported response categories
For the three different BHR provocation tests, cut-off values
were previously determined in different populations and
with distinct methods. For the Malmberg method [23], a
PD20 of 0.6mg corresponded to an 80% sensitivity in asth-
matics (n¼ 102) and an 85% specificity in healthy sub-
jects (n¼ 203).
Nieminen et al. [24] retrospectively gathered PD20 values
in an adult population (n¼ 791), including patients with
asthma, allergic rhinitis, chronic bronchitis and healthy sub-
jects. This study yielded the following cut-off categories of
BHR: no reaction, PD20 >2.6mg; mild, 2.6–0.61mg; moder-
ate, 0.6–0.15mg; marked, <0.15mg.
Sovij€arvi et al. [4] acquired cut-off values for histamine
challenge testing with clinical material, including patients
with asthma (n¼ 64), chronic bronchitis (n¼ 71), chronic
rhinitis (n¼ 41) and healthy subjects (n¼ 31). The cut-off
values were classified as the following: no reaction, PD15
>1.6mg; mild, 1.6–0.41mg; moderate, 0.4–0.11mg; marked,
0.1mg. The analyses of the asthmatic patients in the study
[4], showed a sensitivity of 86% and specificity of 92% with
a PD15 cut-off level of 0.1mg and a sensitivity of 66% and
specificity of 100% with a PD15 cut-off level of 0.4mg.
Response-dose slopes and PD
When examining the individual slopes of the response-dose
relationship, the individual slopes were similar between the
methods. We assumed equal method-independent slopes, as
a measure of individual reactivity and obtained PD for each
method with the slopes extracted from the mixed model.
These equivalent PD are very near to the clinically signifi-
cant cut-off values reported by the original studies [4,23,24].
Moderate and mild hyperreactivity
The equivalent dose-response slopes are similar for the PD
reported by Sovij€arvi et al. [4] and Nieminen [24], when
observing the cut-off between moderate and mild hyperreac-
tivity (see bold values in Table 3). We can assert that these
cut-off values are interchangeable. With the Malmberg
method, this equivalent response-dose slope translates into
an analogous provocative dose of approximately 0.8mg.
Ehrs et al. [23] reported a cut-off value for the Malmberg
method of 0.6mg methacholine to distinguish between
healthy and asthmatic subjects, which equals provocative
doses of 0.4mg for Nieminen and 0.3mg histamine for
Sovij€arvi. This cut-point value lies between moderate and
marked hyperreactivity.
Marked hyperreactivity
When observing the corresponding cut-off values for
marked hyperreactivity, a similarity between the Sovij€arvi
and Nieminen provocative doses is seen. For the Malmberg
method, no provocative dose has previously been reported
to define marked hyperreactivity. Our results imply that this
provocative dose corresponds to 0.3mg of methacholine
with the Malmberg method.
No hyperreactivity
The borders for classifying a normal reaction (no hyperreac-
tivity) were more far away, when analysing the Sovij€arvi and
Nieminen methods. This may suggest differences in the
grading of no hyperreactivity between the Sovij€arvi and
Nieminen methods.
Previous studies
Our results find support from Juusela et al. [5], who found
good agreement between the cut-off values for moderate
and as well as marked BHR between the dosimetric methods
of Sovij€arvi and Nieminen but found only a moderate agree-
ment for the cut-off values for a negative reaction.
Response-dose slopes have been previously investigated and
have been found able to discern between healthy and asth-
matic subjects [25]. These slopes were proven useful in
population studies [26], with good repeatability [27].
Preceding Malmberg method analyses of the response-dose
slopes and PD20 have found values in different studies and
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populations, that when compared to our dose-response
slopes and provocative dose equivalences, show similar val-
ues [12,28,29]. However, to the best of our knowledge, there
are no earlier comparisons between the Malmberg and other
BHR testing methods.
Utility
We provided an exhaustive table with equivalent provocative
doses as reference for clinical application. Our reference
table provides aid when comparing patient results obtained
with different methods. Additionally, it facilitates compari-
son of epidemiological results. Recent population-based
studies and clinical trials utilise one of the aforementioned
testing methods each: Sovij€arvi [30–37], Malmberg [38–41]
or Nieminen [14,42–44]; the reference table may serve the
purpose of offering comparisons in these example studies
and others, or in future studies. Nowadays, the supply
of histamine as a challenge test substance is very limited,
therefore, a comparison to other challenge methods was
also needed.
Strengths and limitations
The strengths of this study are employing the unmodified
equipment and the original protocols for the comparison,
except for omitting a step with inhalation of saline solution
described in the Nieminen method. This omission is due to
practicability. Additionally, we performed carefully the chal-
lenge tests with varying test order. Nevertheless, the number
of volunteers acquired was limited, due to lack of motiv-
ation in potential study candidates to perform three chal-
lenge tests, availability of the tests and interruptions in the
three-day protocol. Although the number of participants
could represent a limiting factor, we calculated a priori a
minimum of 30 participants needed for the study and ful-
filled this objective. Our results indicate a difference in the
methods studied, giving discordant quantities of positive
results. However, we showed that evaluating the FEV1
reduction and dose-response slopes resulted in similarities
between the methods at the level of PD15 or PD20, when
regarding the diagnostic cut-off levels for asthma. This was
more evident with the Sovij€arvi and Nieminen methods.
Conclusion
In conclusion, we provided equivalent provocative doses for
the Per Malmberg, Nieminen, and Sovij€arvi methods of
BHR testing and determined that the available cut-off values
for a moderate reaction and a marked reaction between the
Sovij€arvi and Nieminen methods are similar. Additionally,
we deduced cut-off values for the Malmberg method. The
response-dose slopes can be used when comparing BHR
methods in further physiological research.
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